KR20030091952A - 선택적인 암 치료용의 특이적 인간 항체 - Google Patents

선택적인 암 치료용의 특이적 인간 항체 Download PDF

Info

Publication number
KR20030091952A
KR20030091952A KR10-2003-7008885A KR20037008885A KR20030091952A KR 20030091952 A KR20030091952 A KR 20030091952A KR 20037008885 A KR20037008885 A KR 20037008885A KR 20030091952 A KR20030091952 A KR 20030091952A
Authority
KR
South Korea
Prior art keywords
polypeptide
peptide
seq
cell
amino acid
Prior art date
Application number
KR10-2003-7008885A
Other languages
English (en)
Korean (ko)
Inventor
하가이요체베드
라자로비츠자넷
거이라첼
립쉬츠올리
스잔톤이스터
레바논아비그도
플락신대니얼
페레츠투비아
Original Assignee
사비언트 파마슈티컬즈 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사비언트 파마슈티컬즈 인코퍼레이티드 filed Critical 사비언트 파마슈티컬즈 인코퍼레이티드
Publication of KR20030091952A publication Critical patent/KR20030091952A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR10-2003-7008885A 2000-12-29 2001-12-31 선택적인 암 치료용의 특이적 인간 항체 KR20030091952A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
US09/751,181 2000-12-29
PCT/US2001/049440 WO2002059264A2 (fr) 2000-12-29 2001-12-31 Anticorps humains specifiques pour la therapie selective du cancer

Publications (1)

Publication Number Publication Date
KR20030091952A true KR20030091952A (ko) 2003-12-03

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7008885A KR20030091952A (ko) 2000-12-29 2001-12-31 선택적인 암 치료용의 특이적 인간 항체

Country Status (15)

Country Link
EP (1) EP1353937A4 (fr)
JP (1) JP2004524023A (fr)
KR (1) KR20030091952A (fr)
CN (1) CN100374456C (fr)
AU (1) AU2002246737B2 (fr)
BR (1) BR0116763A (fr)
CA (1) CA2433227A1 (fr)
CZ (1) CZ20031983A3 (fr)
HU (1) HUP0400775A2 (fr)
IL (1) IL156690A0 (fr)
MX (1) MXPA03005944A (fr)
NZ (1) NZ527173A (fr)
PL (1) PL365758A1 (fr)
RU (1) RU2316564C2 (fr)
WO (1) WO2002059264A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05000271A (es) * 2002-07-01 2005-03-31 Savient Pharmaceuticals Inc Composiciones y metodos para tratamiento terapeutico.
WO2005005455A2 (fr) * 2003-06-30 2005-01-20 Bio-Technology General (Israel)Ltd. Anticorps humains specifiques
EA012970B1 (ru) 2005-04-26 2010-02-26 Пфайзер Инк. Антитела против р-кадгерина
CA2747154C (fr) 2008-12-19 2015-11-10 Philogen S.P.A. Immunocytokines pour therapie tumorale avec agents chimiotherapiques
CN110437321A (zh) * 2010-07-09 2019-11-12 阿菲博迪公司 多肽
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
DK3590962T3 (da) * 2014-10-23 2021-12-13 Singh Molecular Medicine Llc Enkeltdomæneantistoffer rettet mod intracellulære antigener
CA2970255A1 (fr) * 2014-12-17 2016-06-23 Intrexon Corporation Fragments variables intercales a chaine unique
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
CN108290940B (zh) * 2015-10-01 2021-12-07 圣拉斐尔医院有限公司 Tcr及其用途
WO2017087789A1 (fr) * 2015-11-19 2017-05-26 Revitope Limited Complémentation de fragment d'anticorps fonctionnel pour un système à deux composants pour la destruction redirigée de cellules indésirables
CR20220408A (es) * 2016-09-14 2022-10-20 Teneobio Inc ANTICUERPOS DE UNIÓN A CD3(Divisional del Expediente 2019-198)
CA3197828A1 (fr) * 2020-11-13 2022-05-19 Laurens Kruidenier Methodes, systemes et kits pour le traitement d'une maladie inflammatoire ciblant tl1a

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002479A2 (fr) * 1995-06-30 1997-01-23 Yale University Anticorps anti-tumoraux monoclonaux humains
BR9806793A (pt) * 1997-01-22 2000-05-16 Univ Texas Processos e composições de fator tissular para coagulação e tratamento de tumores.

Also Published As

Publication number Publication date
CN1551886A (zh) 2004-12-01
WO2002059264A2 (fr) 2002-08-01
MXPA03005944A (es) 2005-04-29
PL365758A1 (en) 2005-01-10
EP1353937A4 (fr) 2005-04-13
EP1353937A2 (fr) 2003-10-22
RU2003123100A (ru) 2005-03-10
BR0116763A (pt) 2004-03-09
CZ20031983A3 (cs) 2005-07-13
HUP0400775A2 (en) 2007-05-02
IL156690A0 (en) 2004-01-04
CN100374456C (zh) 2008-03-12
RU2316564C2 (ru) 2008-02-10
JP2004524023A (ja) 2004-08-12
NZ527173A (en) 2006-03-31
WO2002059264A3 (fr) 2003-03-06
AU2002246737B2 (en) 2007-03-01
CA2433227A1 (fr) 2002-08-01

Similar Documents

Publication Publication Date Title
US20070149768A1 (en) Specific human antibodies for selective cancer therapy
US20040002450A1 (en) Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001822A1 (en) Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20090220486A1 (en) Antibodies and uses thereof
EP1268800A2 (fr) Elements de liaison specifiques de la mucine-1 et techniques d'utilisation
AU2001249760A1 (en) Mucin-1 specific binding members and methods of use thereof
US20040001839A1 (en) Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
AU2002246737B2 (en) Specific human antibodies for selective cancer therapy
AU2002246737A1 (en) Specific human antibodies for selective cancer therapy
MXPA03005945A (es) Moleculas aisladas que comprenden epitopes que contienen grupos sulfato, anticuerpos para tales epitopes y usos de ellos.
JP2005503756A5 (fr)
US20040202665A1 (en) Compositions and methods for therapeutic treatment
CA2491363A1 (fr) Anticorps et leurs applications
KR20050059001A (ko) 치료적 처리를 위한 조성물 및 방법
JP2007528711A (ja) 抗体及びその使用
US20040208877A1 (en) Antibodies and uses thereof
KR102698752B1 (ko) 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
AU2002246738A1 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application